Use of nonimaging nuclear medicine techniques to assess the effect of flunixin meglumine on effective renal plasma flow and effective renal blood flow in healthy horses.

The research article studies the effect of flunixin meglumine, a non-steroidal anti-inflammatory drug (NSAID), on the renal function of healthy horses using nonimaging nuclear medicine techniques.

Methodology

• The scientists conducted a study on six healthy horses to understand how flunixin meglumine, a non-steroidal anti-inflammatory drug, affects renal function. This was executed by using nonimaging nuclear medicine techniques, which don’t involve taking pictures of the organ or tissue being studied, but rather measure its function.
• They assessed the Effective Renal Plasma Flow (ERPF) and Effective Renal Blood Flow (ERBF), two parameters central to understanding the kidneys’ performance. These were calculated through the plasma clearance of 131I-orthoiodohippuric acid (a compound used in medicine to quantify renal blood flow) before and after the administration of flunixin meglumine.

Findings

• The mean (or average) ERPF and ERBF were 6.03 ml/min/kg and 10.7 ml/min/kg respectively before the administration of the NSAID.
• After the drug was administered, the ERPF and ERBF respectively dropped to 5.7 ml/min/kg and 9.7 ml/min/kg. This indicates that flunixin meglumine does have an impact on renal function by reducing blood flow to the kidneys.

Interpretation

• Despite the decrease in ERPF and ERBF after the administration of flunixin meglumine, the scientists have stated that the difference is not statistically significant. This means that although the values do decrease, the decrease might not be substantial enough to clearly attribute it to the effect of the drug. Other variables might also be at play influencing the results.
• This infers that while flunixin meglumine does affect renal function to a certain degree, it may not substantially alter the kidneys’ functionality in healthy horses. Further research is needed to confirm this hypothesis and to understand the potential consequences of its use in horses with compromised renal function.